- Home
- » Tags
- » Dolutegravir
Top View
- Triumeq, INN-Dolutegravir, Abacavir, Lamivudine
- Antivirals – HIV Combinations Medical Policy No
- Dolutegravir Regimen Statistically Superior To
- Download File
- Reseptregisteret 2014–2018 the Norwegian Prescription Database 2014–2018
- DOVATO (Dolutegravir and Lamivudine) Tablets, for Oral Use Increased Risk for Worsening Or Development of Transaminase Elevations Initial U.S
- TABLE 2. HIV Treatment Pipeline 2003–2012 Class Drug Name Generic Name Brand Name Sponsor 2003 2004 2005 2006 2007 2008 2009 2
- Chemical Diversity and Activity Profiles of HIV-1 Reverse Transcriptase
- Estonian Statistics on Medicines 2017 1/42
- GLASS Methodology for Surveillance of National Antimicrobial Consumption
- TIVICAY(Dolutegravir)
- (TLD) Transition General Information for Clients, Clinicians, Counselors, and Other Service Providers
- Drug Interactions with Antiretroviral Medications
- Dolutegravir Was Approved for Use by the United States HIV Treatment Food and Drug Administration (U.S
- Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide from Dolutegravir Plus Abacavir and Lamivudine In
- N204-790 Dolutegravir Clinpharm PREA
- Switching & Second-Line
- Tivicay, INN-Dolutegravir
- Application for Inclusion of Tenofovir Disoproxil Fumarate/Lamivudine/Dolutegravir (TLD) Tablets on the WHO Model List of Essential Medicines (EML)
- ATC-Index Mit DDD-Angaben Für Deutschland Im Jahre 2019
- Risks and Benefits of Dolutegravir- and Efavirenz-Based Strategies For
- HIV Post-Exposure Prophylaxis (PEP) Kits for Occupational/Non-Occupational HIV Exposure Occurring in UN Personnel and Dependents
- Effect of Antiretroviral Drug Dolutegravir on Mitochondrial Function
- (12) United States Patent (10) Patent No.: US 9,708,342 B2 Carra Et Al
- Dolutegravir Dolutegravir with Other Drugs
- JULUCA™ (Dolutegravir Sodium-Rilpivirine Hydrochloride) Oral Tablet
- Risks and Benefits of Dolutegravir-Based Antiretroviral Drug Regimens in Sub-Saharan Africa: a Modelling Study
- (Dolutegravir) Film-Coated Tablets 1 NAME of the MEDICINE
- Dolutegravir PK Fact Sheet Reviewed March 2016 Page 1 of 2 for Personal Use Only
- Dolutegravir Call the Clinic Or Discuss Them at Your Next 50 Mg (1 Yellow Tablet) Once Daily Visit
- TIVICAY Tablets: 10 Mg, 25 Mg, and 50 Mg (3) TIVICAY Safely and Effectively
- Dolutegravir (Tivicay)
- Darunavir and Dolutegravir Combination Therapy in ART
- Information on Crushing and Liquid Drug Formulations
- A/S: 480 X 680 Mm Black
- Efavirenz and Dolutegravir a Tale of Two Arvs
- 2013 Pipeline Report
- Recent Developments in HIV Treatment and Their Dissemination in Poor
- First Case of Dolutegravir and Darunavir/R Multi Drug-Resistant HIV
- Page: Treatment-Drugs
- TIVICAY (Dolutegravir) Tablets for Oral Use Stopping Treatment May Result in a Life-Threatening Reaction
- Tivicay, INN-Dolutegravir
- The Pharmacokinetics of Dolutegravir Ritonavir-Boosted Protease
- Identification of Novel Compounds Against Three Targets of SARS Cov-2 Coronavirus by Combined Virtual Screening and Supervised Machine Learning
- HIV, HCV, TB: 2012 Pipeline Report, TAG and I-Base
- Dolutegravir Plus Lamivudine Two-Drug Regimen
- 2011 Pipeline Report Second Edition
- Triumeq (Abacavir/Dolutegravir/Lamivudine) Tablets, for the Treatment of Human Immunodeficiency Virus Type 1 (HIV-1) Infection in Pediatric Patients Weighing ≥ 40 Kg
- THE DOLUTEGRAVIR OPPORTUNITY Managing Supply Chain Risk for the Introduction of a New Antiretroviral (ARV) Medicine
- ESAC-Net Reporting Protocol 2018.Docx Introduction